Öztürk Ateş

16PUBLICATIONS
152CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunityOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 26, 2026
Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.

|Aug 07, 2026
Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer.

|Jun 26, 2026
Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|May 27, 2026
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.

|Mar 28, 2026
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Sedat Yıldız, Hacer Demir, Talha Özüdoğru

Pageof 3

Frequent Collaborators

4 joint publications

Berkan Karabuğa

4 joint publications

Elif Şahin

3 joint publications

Sinem Akbas

3 joint publications

İlknur Deliktaş Onur